



## BOARD OF DIRECTORS

### ROBERT FILDES, PH.D. (CHAIRMAN)

Dr. Fildes currently serves as President of SB2 Inc. Dr. Fildes has extensive experience in the biotechnology and pharmaceutical sector, including terms as President & CEO of Cetus Corporation, President of Biogen Inc., and Vice President of Operations for the Industrial Division of Bristol-Myers Squibb Company. He is currently a director on numerous boards of publicly and privately traded biotechnology companies. Dr. Fildes holds a D.C.C. degree in Microbial Biochemistry as well as a Ph.D. in Biochemical Genetics from the University of London.

### MICHAEL J. ABRAMS, PH.D., PRESIDENT & CHIEF EXECUTIVE OFFICER

Dr. Abrams was the founding CEO of AnorMED, Inc and led that company as President and CEO for ten years. AnorMED discovered and developed Mozobil, a drug for improving stem cell mobilization for patients undergoing stem cell transplantation. Mozobil was approved by FDA in 2008 and AnorMED was acquired by Genzyme Corp. in 2006 for \$580M. Prior to AnorMED, Abrams was Manager Biomedical Research for Johnson Matthey, plc where he led the spin-off of the biomedical research group to form AnorMED. Abrams has a Ph.D. in Chemistry from the Massachusetts Institute of Technology and a BA in Chemistry from Bowdoin College. In 2009 he was a co-recipient of the Georg Charles de Hevesy Nuclear Pioneer Award from the Society of Nuclear Medicine for his work in the invention of the radiopharmaceutical, Cardiolite.

### PAT BRADY, M.B.A.

Mr. Brady is Vice President Investments, Life Sciences at Growthworks Capital. He joined Growthworks in 1998 with eight years of business and consulting experience with emerging companies. He was heavily involved in taking two companies public - one TSE listed and one listed on the NASDAQ. Mr. Brady has an M.B.A. from the University of Western Ontario. He sits on the boards of Celator Technologies Inc., NeuroMed Technologies, NeuroStream Technologies, Protiva Biotherapeutics, and Twinstrand Therapeutics.

### Scientific Advisory Board:

B. Brett Finlay, Ph.D., O.C.  
F.R.S.C.

R.E.W.(Bob)Hancock,Ph.D.,  
O.C., F.R.S.C.

Stanley Falkow, Ph.D.

AnthonyChow,M.D.,F.R.C.P.,  
F.A.C.P.

H. Grant Stiver, M.D.

Walter Singleton, M.D.

### Contact Information

InimexPharmaceuticalsInc.  
8540 Baxter Place  
Burnaby, British Columbia  
Canada V5A 4T8

P: 604-225-2251  
F: 604-225-2257

[www.inimexpharma.com](http://www.inimexpharma.com)  
[info@inimexpharma.com](mailto:info@inimexpharma.com)

### BRENDA IRWIN, M.B.A.

Ms. Irwin is Director, Venture Capital for BDC Venture Capital. Her focus is on biotechnology investments. Her approach is largely the result of an initial career in the computer industry as marketing manager for a national distributor and her experience as science educator for the North York Board of Education. Eight years of professional leadership paved the way to becoming an investment professional. She participates as guest speaker at life sciences and high tech conferences. Ms. Irwin holds a Bachelor of Science degree in Human Biology and Biomedical Science from the University of Guelph and an M.B.A from the University of British Columbia.

### JOHN R. NORTH, PH.D., CHIEF OPERATING OFFICER

Dr. North most recently served as Sr. Vice President, Scientific Affairs and Chief Scientific Officer of QLT, Inc. Prior to joining QLT, Dr. North was Managing Director of Monotech Laboratories Ltd., Biotechnology Consultant at PA Technology Ltd. and spent 12 years with various U.K. and U.S.-based subsidiaries within the Beaufour Ipsen Group, most recently as Head of Exploratory Development at Ipsen International in the U.K. Dr. North received a Ph.D. in Immunology and an M.A. in Natural Sciences from the University of Cambridge, England.

### STEPHANIE MONAGHAN O'BRIEN, ESQ.

Ms. O'Brien represents Morningside Venture Investments. Ms. O'Brien has extensive experience working with venture backed technology companies. She focuses on early stage companies, working with CEOs on building the management team and developing business plans. She currently serves on several private company boards, including Serica Technology, Inc. cMarket, Inc and I-Behavior, Inc. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law. Prior to attending law school, Stephanie worked for Chase Manhattan Bank, N.A, where she completed the loan officer credit training program and then worked in international portfolio analysis. After law school, Stephanie spent nine years as a corporate lawyer with Hale and Dorr in both the Boston and Washington, D.C. offices, working in venture capital finance and start-up companies, primarily biotechnology companies.



## MANAGEMENT TEAM



MICHAEL J. ABRAMS, PH.D., PRESIDENT & CHIEF EXECUTIVE OFFICER

Dr. Abrams was the founding CEO of AnorMED, Inc and led that company as President and CEO for ten years. AnorMED discovered and developed Mozobil, a drug for improving stem cell mobilization for patients undergoing stem cell transplantation. Mozobil was approved by FDA in 2008 and AnorMED was acquired by Genzyme Corp. in 2006 for \$580M. Prior to AnorMED, Abrams was Manager Biomedical Research for Johnson Matthey, plc where he led the spin-off of the biomedical research group to form AnorMED. Abrams has a Ph.D. in Chemistry from the Massachusetts Institute of Technology and a BA in Chemistry from Bowdoin College. In 2009 he was a co-recipient of the Georg Charles de Hevesy Nuclear Pioneer Award from the Society of Nuclear Medicine for his work in the invention of the radiopharmaceutical, Cardiolite.



JOHN R. NORTH, PH.D., CHIEF OPERATING OFFICER

Dr. North most recently served as Sr. Vice President, Scientific Affairs and Chief Scientific Officer of QLT, Inc. Prior to joining QLT, Dr. North was Managing Director of Monotech Laboratories Ltd., Biotechnology Consultant at PA Technology Ltd. and spent 12 years with various U.K. and U.S.-based subsidiaries within the Beaufour Ipsen Group, most recently as Head of Exploratory Development at Ipsen International in the U.K. Dr. North received a Ph.D. in Immunology and an M.A. in Natural Sciences from the University of Cambridge, England.



OREOLA DONINI, PH.D., SENIOR DIRECTOR, PRECLINICAL R&D

Dr. Donini was a Program Director at Kinetek Pharmaceuticals Inc. and managed a team which provided molecular modelling, bioinformatics, and cheminformatics services. Dr. Donini has received numerous graduate awards for her research on in silico design and computational chemistry. She received her Ph.D. from Queen's University in Kingston, Ontario and completed post-doctoral studies at the University of California San Francisco.



MARTIN (MARTY) MCCONNELL, C.A., CHIEF FINANCIAL OFFICER

For the past five years Marty has worked with emerging high tech and Biotech companies as part-time CFO focused on strategic financial issues. For the prior 18 years he was CFO for two midsize public (TSX, Nasdaq) Canadian high tech companies, from 1993 to 2002 with Spectrum Signal Processing Inc. and from 1985 to 1993 at Epic Data International Inc. Mr. McConnell holds a B. Comm. from the University of British Columbia and is a Chartered Accountant.